1.5/m2) 120mg/day(BSA=>
Sponsors
The University of Tokyo Hospital, Hokkaido Pancreatic Cancer Study Group (HOPS)
Conditions
Borderline and Locally advanced pancreatic cancerpancreatic cancer
Phase 2
A phase 2 study of combination neoadjuvant chemotherapy with gemcitabine S-1 and leucovorin in patients with borderline and locally advanced pancreatic cancer
Active, not recruitingJPRN-UMIN000012480
Start: 2013-12-04Target: 24Updated: 2026-06-29
Neoadjuvant S-1 therapy for resectable pancreatic cancer patients; A phase2 study
Active, not recruitingJPRN-UMIN000013031
Start: 2013-11-01Target: 50Updated: 2026-06-29